氯吡格雷联合依折麦布治疗冠心病心绞痛的效果及安全性分析

Effect and safety analysis of clopidogrel combined with ezetimibe in the treatment of angina pectoris of coronary heart disease

目的分析冠心病心绞痛临床治疗中应用依折麦布、氯吡格雷的效果及安全性。方法选取80例冠心病心绞痛患者,随机分为研究组(40例)、对照组(40例)。对照组单独使用依折麦布治疗,研究组使用依折麦布联合氯吡格雷治疗。比较两组临床指标、总胆固醇(TC)、甘油三酯(TG)、内皮素-1(ET-1)、一氧化氮(NO)以及用药安全性。结果治疗后,研究组患者心绞痛持续时间(8.89±0.71)min/次短于对照组的(9.32±0.86)min/次,心绞痛发作频率(2.03±0.15)次/周低于对照组的(4.59±0.29)次/周,差异具统计学意义(P<0.05)。治疗后,研究组患者TG、TC分别为(1.18±0.16)、(3.16±0.82)mmol/L,比对照组的(1.59±0.23)、(4.72±1.01)mmol/L低,差异具统计学意义(P<0.05)。治疗后,研究组患者ET-1(67.45±5.23)ng/L低于对照组的(74.16±4.12)ng/L,而NO(82.57±5.18)μmol/L高于对照组的(71.73±4.15)μmol/L,差异具统计学意义(P<0.05)。治疗后,研究组患者不良反应发生率7.50%与对照组的10.00%比较,差异无统计学意义(P>0.05)。结论临床治疗冠心病心绞痛的过程中应用依折麦布、氯吡格雷联合治疗具有更加明显的疗效,能够改善患者的血脂水平,使其ET-1、NO指标得到改善,且患者联合用药后并不会有严重的不良反应,具有较高的安全性。

Objective To analyze the effect and safety of clopidogrel combined with ezetimibe in the treatment of angina pectoris of coronary heart disease.Methods A total of 80 patients with angina pectoris of coronary heart disease were randomly divided into a study group(40 cases)and a control group(40 cases).The control group was treated with ezetimibe alone,and the study group was treated with ezetimibe combined with clopidogrel.The clinical indicators,total cholesterol(TC),triglyceride(TG),endothelin-1(ET-1),nitric oxide(NO),and drug safety of the two groups were compared.Results After treatment,the duration of angina pectoris of(8.89±0.71)min/time in the study group was shorter than(9.32±0.86)min/time in the control group,and the frequency of angina pectoris of(2.03±0.15)times/week was lower than(4.59±0.29)times/week in the control group.The difference was statistically significant(P<0.05).After treatment,TG and TC in the study group were(1.18±0.16)and(3.16±0.82)mmol/L,which were lower than(1.59±0.23)and(4.72±1.01)mmol/L in the control group,and the difference was statistically significant(P<0.05).After treatment,ET-1 of(67.45±5.23)ng/L in the study group was lower than(74.16±4.12)ng/L in the control group,and NO of(82.57±5.18)μmol/L was higher than(71.73±4.15)μmol/L in the control group.The difference was statistically significant(P<0.05).After treatment,there was no significant difference in the incidence of adverse reactions between the study group(7.50%)and the control group(10.00%)(P>0.05).Conclusion In the clinical treatment of angina pectoris of coronary heart disease,the combined application of ezetimibe and clopidogrel has a more obvious effect,which can improve the blood lipid level and indicators of ET-1 and NO.Moreover,the combination of drugs in patients does not cause serious adverse reactions,which has a high safety.